Stock Events

Stock Events

Adicet Bio 

$6.81
0
+$0+0% Wednesday 05:24

Statistics

Day High
6.81
Day Low
6.81
52W High
-
52W Low
-
Volume
8
Avg. Volume
-
Mkt Cap
1.04B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Oct 18
$0.07
Jun 18
$0.07
Mar 18
$0.46
Dec 17
$0.46
Sep 17
$0.46
10Y Growth
N/A
5Y Growth
N/A
3Y Growth
N/A
1Y Growth
N/A

Earnings

12MayExpected
Q3 2025
Q4 2025
Next
-11
-8.3
-5.61
-2.91
Expected EPS
-11
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-234.24MNet Income

Analyst Ratings

$48.33Average Price Target
The highest estimate is 100.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow ACET.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Fate Therapeutics
FATE
Mkt Cap155.7M
Fate Therapeutics is focused on the development of programmed cellular immunotherapies for cancer and immune disorders, similar to Adicet Bio's focus on cell therapies for cancer, making them direct competitors in the cell therapy space.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics operates in the field of allogeneic CAR T cell therapies, directly competing with Adicet Bio's allogeneic cell therapy approach for treating cancer.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics is engaged in gene editing and CAR-T therapy developments, competing in the innovative therapy space including cancer treatments, overlapping with Adicet Bio's focus areas.
Novartis
NVS
Mkt Cap237.61B
Novartis is a large pharmaceutical company with a strong presence in the cell therapy market, including Kymriah, a CAR-T therapy for cancer, making it a competitor to Adicet Bio.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, through its acquisition of Kite Pharma, has become a leader in CAR-T therapy for cancer, directly competing with Adicet Bio's cell therapy approaches.
Precigen
PGEN
Mkt Cap1.46B
Precigen is a biotechnology company that develops gene and cell therapies, including CAR-T therapies for cancer, making it a competitor in the same field as Adicet Bio.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics specializes in genomic medicine, including gene therapy, gene editing, and cell therapy for cancer and other diseases, competing in the same innovative therapy areas as Adicet Bio.

About

Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also engages in the development of ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors. Adicet Bio, Inc. is based in Boston, Massachusetts.
Show more...
CEO
ISIN
US0070022076

Listings

LSE
GB
0HX7.LSE
XNAS
US
ACET
F
DE
1IJ.F
BOATS
BOATS
ACET.BOATS

0 Comments

Share your thoughts

FAQ

What is Adicet Bio stock price today?▼
The current price of ACET.BOATS is $6.81 USD — it has increased by +0% in the past 24 hours. Watch Adicet Bio stock price performance more closely on the chart.
What is Adicet Bio stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adicet Bio stocks are traded under the ticker ACET.BOATS.
What is Adicet Bio market cap?▼
Today Adicet Bio has the market capitalization of 1.04B
When is the next Adicet Bio earnings date?▼
Adicet Bio is going to release the next earnings report on May 12, 2026.
What were Adicet Bio earnings last quarter?▼
ACET.BOATS earnings for the last quarter are -2.94 USD per share, whereas the estimation was -2.91 USD resulting in a -1.03% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Adicet Bio revenue for the last year?▼
Adicet Bio revenue for the last year amounts to 0 USD.
What is Adicet Bio net income for the last year?▼
ACET.BOATS net income for the last year is -234.24M USD.
Does Adicet Bio pay dividends?▼
Yes, ACET.BOATS dividends are paid semi-annual. The last dividend per share was 0.07 USD. As of today, Dividend Yield (FWD)% is 0%.
When did Adicet Bio complete a stock split?▼
Adicet Bio has not had any recent stock splits.